About DNage
DNage is a company based in Leiden (Netherlands) founded in 2004 by Jan Hoeijmakers, Wim Vermeulen, Roland Kanaar, and Gijsbertus Van Der Horst was acquired by Pharming Group in October 2006.. DNage has raised $1.94 million across 1 funding round from investors including Pharming Group, Life Sciences Partners and Inventages. DNage offers products and services including Dietary Supplement. DNage operates in a competitive market with competitors including Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Leiden, Netherlands
- Founders Jan Hoeijmakers, Wim Vermeulen, Roland Kanaar, Gijsbertus Van Der Horst
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Dnage Products N.V.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.94 M (USD)
in 1 rounds
-
Latest Funding Round
$1.94 M (USD), Series A
Apr 13, 2005
-
Investors
Pharming Group
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Pharming Group
(Oct 16, 2006)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DNage
DNage offers a comprehensive portfolio of products and services, including Dietary Supplement. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Supplement for DNA damage repair to support anti-ageing and health benefits.
Funding Insights of DNage
DNage has successfully raised a total of $1.94M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.94 million completed in April 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $1.9M
-
First Round
First Round
(13 Apr 2005)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2005 | Amount | Series A - DNage | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in DNage
DNage has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Pharming Group, Life Sciences Partners and Inventages. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in life sciences businesses are managed.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Recombinant protein-based therapeutics for rare diseases are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by DNage
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - DNage
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Dnage Comparisons
Competitors of DNage
DNage operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for rare genetic diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about DNage
When was DNage founded?
DNage was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Where is DNage located?
DNage is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Is DNage a funded company?
DNage is a funded company, having raised a total of $1.94M across 1 funding round to date. The company's 1st funding round was a Series A of $1.94M, raised on Apr 13, 2005.
What does DNage do?
DNage was founded in 2004 as a spin-off from the Department of Genetics at Erasmus Medical Center Rotterdam and is located in Leiden, Netherlands. Therapies targeting ageing diseases caused by DNA damage are developed, with programs in neurodegeneration, bone disease, and related pathologies. The lead product, Prodarsana small molecule combination for Cockayne Syndromewas approved by the FDA in August 2009, after acquisition by Pharming Group in 2006.
Who are the top competitors of DNage?
DNage's top competitors include Alnylam, BioMarin Pharmaceutical and Pharvaris.
What products or services does DNage offer?
DNage offers Dietary Supplement.
Who are DNage's investors?
DNage has 3 investors. Key investors include Pharming Group, Life Sciences Partners, and Inventages.